{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:47:36Z","timestamp":1792205256109,"version":"4.4.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.micpath.2025.107794","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T22:04:00Z","timestamp":1749420240000},"page":"107794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Application of antimicrobial drugs in Mycobacterium tuberculosis and research progress"],"prefix":"10.1016","volume":"206","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daxing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2025.107794_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41579-018-0013-4","article-title":"Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis","volume":"16","author":"Ehrt","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.micpath.2025.107794_bib2","first-page":"61","article-title":"Microbial pathogenesis: an insight into Mycobacterium tuberculosis","volume":"20","author":"Manjula","year":"2002","journal-title":"Indian J. Med. Microbiol."},{"key":"10.1016\/j.micpath.2025.107794_bib3","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1128\/IAI.66.5.2221-2229.1998","article-title":"Use of a Mycobacterium tuberculosis H37Rv bacterial artificial chromosome library for genome mapping, sequencing, and comparative genomics","volume":"66","author":"Brosch","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.micpath.2025.107794_bib4","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1128\/JB.182.22.6322-6330.2000","article-title":"Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence","volume":"182","author":"Stinear","year":"2000","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.micpath.2025.107794_bib5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/31159","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"393","author":"Cole","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.micpath.2025.107794_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2019.151353","article-title":"Mycobacterium tuberculosis DosR regulon gene Rv2004c contributes to streptomycin resistance and intracellular survival","volume":"309","author":"Doddam","year":"2019","journal-title":"Int. J. Med. Microbiol."},{"key":"10.1016\/j.micpath.2025.107794_bib7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1183\/13993003.00436-2015","article-title":"A tale of two global emergencies: tuberculosis control efforts can learn from the Ebola outbreak","volume":"46","author":"Nathavitharana","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2025.107794_bib8","series-title":"Global Tuberculosis Report 2021: Supplementary Material","year":"2022"},{"key":"10.1016\/j.micpath.2025.107794_bib9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1473-3099(03)00741-2","article-title":"Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection","volume":"3","author":"Tufariello","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat. Rev Dis. Primers"},{"key":"10.1016\/j.micpath.2025.107794_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nrmicro2797","article-title":"Global tuberculosis control: lessons learnt and future prospects","volume":"10","author":"Lienhardt","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.micpath.2025.107794_bib12","first-page":"685","volume":"vol. 20","author":"Dartois","year":"2022"},{"key":"10.1016\/j.micpath.2025.107794_bib13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.micpath.2025.107794_bib14","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021154","article-title":"The tuberculosis drug discovery and development pipeline and emerging drug targets","volume":"5","author":"Mdluli","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"9","key":"10.1016\/j.micpath.2025.107794_bib15","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cmi.2023.07.013","article-title":"Recent advances in the treatment of tuberculosis","volume":"30","author":"Motta","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.micpath.2025.107794_bib16","first-page":"45","volume":"vol. 11","author":"Cohen","year":"2019"},{"key":"10.1016\/j.micpath.2025.107794_bib17","article-title":"Genomic sequencing from sputum for tuberculosis disease diagnosis","volume":"vol. 61","author":"Nilgiriwala","year":"2023"},{"issue":"6","key":"10.1016\/j.micpath.2025.107794_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01354-2017","article-title":"A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis","volume":"50","author":"Miotto","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2025.107794_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00263-9","article-title":"Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis","author":"Schwab","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib20","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/AAC.41.5.1004","article-title":"Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium","volume":"41","author":"Collins","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14745\/ccdr.v43i34a01","article-title":"Tuberculosis (TB): latent tuberculosis infection: an overview","volume":"43","author":"Kiazyk","year":"2017","journal-title":"Can. Commun. Dis. Rep."},{"key":"10.1016\/j.micpath.2025.107794_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.tube.2015.04.003","article-title":"Latent tuberculosis infection\u2013revisiting and revising concepts","volume":"95","author":"Salgame","year":"2015","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2025.107794_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","article-title":"Preventive therapy for latent tuberculosis infection\u2014the promise and the challenges","volume":"56","author":"Fox","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40506-017-0135-7","article-title":"Treatment of latent tuberculosis infection","volume":"9","author":"Tang","year":"2017","journal-title":"Curr. Treat. Options Infect. Dis."},{"issue":"2","key":"10.1016\/j.micpath.2025.107794_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/microbiolspec.TNMI7-0039-2016","article-title":"Treatment of latent tuberculosis infection","volume":"5","author":"Haley","year":"2017","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2025.107794_bib26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.amepre.2018.04.030","article-title":"Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis","volume":"55","author":"Njie","year":"2018","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1469-0691.2004.00758.x","article-title":"Tuberculosis in HIV-infected patients: a comprehensive review","volume":"10","author":"Aaron","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.micpath.2025.107794_bib28","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/resp.13346","article-title":"Latent tuberculosis infection: opportunities and challenges","volume":"23","author":"Chee","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.micpath.2025.107794_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.crohns.2012.05.012","article-title":"Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening","volume":"7","author":"Jauregui-Amezaga","year":"2013","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.micpath.2025.107794_bib30","first-page":"1374","article-title":"Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review","volume":"14","author":"Kunst","year":"2010","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib31","first-page":"294","article-title":"Considerations on two cases of TB meningitis treated with streptomycin","volume":"18","author":"Orlandini","year":"1947","journal-title":"Lattante"},{"key":"10.1016\/j.micpath.2025.107794_bib32","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib33","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib34","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","volume":"400","author":"Mok","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.micpath.2025.107794_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(13)70328-1","article-title":"New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects","volume":"14","author":"Zumla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib36","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.20.1.21781","article-title":"The science of Durban, AIDS 2016","volume":"20","author":"Beyrer","year":"2017","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.micpath.2025.107794_bib37","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib38","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib39","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmi.2014.08.008","article-title":"Treatment outcome of patients with isoniazid mono-resistant tuberculosis","volume":"21","author":"Chien","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.micpath.2025.107794_bib41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1473-3099(17)30076-2","article-title":"Isoniazid-resistant tuberculosis treatment with first-line drugs","volume":"17","author":"Chien","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib42","series-title":"WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment - Drug-Resistant Tuberculosis Treatment","year":"2020"},{"key":"10.1016\/j.micpath.2025.107794_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077712","article-title":"Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region","volume":"8","author":"Coovadia","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2025.107794_bib44","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.micpath.2025.107794_bib45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2213-2600(14)70031-1","article-title":"Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis","volume":"2","author":"Dheda","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib46","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/cid\/ciw002","article-title":"Surgery as an adjunctive treatment for multidrug-resistant tuberculosis: an individual patient data metaanalysis","volume":"62","author":"Fox","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib47","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update","volume":"57","author":"Mirzayev","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2025.107794_bib48","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1473-3099(20)30914-2","article-title":"Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial","volume":"21","author":"Scriba","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib49","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/828939","article-title":"Risk factors for tuberculosis","volume":"2013","author":"Narasimhan","year":"2013","journal-title":"Pulm. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mbs.2019.05.002","article-title":"Problems with the WHO TB model","volume":"313","author":"Wallace","year":"2019","journal-title":"Math. Biosci."},{"key":"10.1016\/j.micpath.2025.107794_bib51","series-title":"Module 2: Screening-Systematic Screening for Tuberculosis Disease","year":"2021"},{"key":"10.1016\/j.micpath.2025.107794_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/rccm.202001-0135OC","article-title":"Culture conversion in patients treated with bedaquiline and\/or delamanid. A prospective multicountry study","volume":"203","author":"Franke","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.micpath.2025.107794_bib53","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/rccm.201311-2106PP","article-title":"Tuberculosis, pulmonary cavitation, and matrix metalloproteinases","volume":"190","author":"Ong","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.micpath.2025.107794_bib55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7861\/clinmedicine.12-1-40","article-title":"Cavitating pulmonary tuberculosis: a global challenge","volume":"12","author":"Saeed","year":"2012","journal-title":"Clin. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib56","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1164\/rccm.201604-0769OC","article-title":"Detection and quantification of differentially culturable tubercle bacteria in sputum from patients with tuberculosis","volume":"194","author":"Chengalroyen","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.micpath.2025.107794_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10916-015-0388-y","article-title":"A review of automatic methods based on image processing techniques for tuberculosis detection from microscopic sputum smear images","volume":"40","author":"Panicker","year":"2016","journal-title":"J. Med. Syst."},{"key":"10.1016\/j.micpath.2025.107794_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040120","article-title":"Why is long-term therapy required to cure tuberculosis?","volume":"4","author":"Connolly","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.micpath.2025.107794_bib59","series-title":"Mycobacteria - Comparative Genomics, Biomarker Identification","author":"Cobongela","year":"2024"},{"key":"10.1016\/j.micpath.2025.107794_bib60","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.biopha.2018.01.115","article-title":"Recent therapeutic approaches for the management of tuberculosis: challenges and opportunities","volume":"99","author":"Patil","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.micpath.2025.107794_bib61","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/IDR.S68351","article-title":"New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid","author":"Brigden","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2025.107794_bib62","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/joim.12264","article-title":"Totally drug\u2010resistant tuberculosis and adjunct therapies","volume":"277","author":"Parida","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijid.2016.08.027","article-title":"Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo","volume":"52","author":"Zhao","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib64","series-title":"Perspectives for Personalized Therapy for Patients with Multidrug\u2010resistant Tuberculosis","first-page":"163","author":"Lange","year":"2018"},{"key":"10.1016\/j.micpath.2025.107794_bib65","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.06288-11","article-title":"Targeting persisters for tuberculosis control","volume":"56","author":"Zhang","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib66","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1473-3099(20)30914-2","article-title":"Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial","volume":"21","author":"Scriba","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri2960","article-title":"Immunological biomarkers of tuberculosis","volume":"11","author":"Walzl","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.micpath.2025.107794_bib68","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1473-3099(13)70034-3","article-title":"Tuberculosis biomarkers discovery: developments, needs, and challenges","volume":"13","author":"Wallis","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00109-007-0157-6","article-title":"Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis","volume":"85","author":"Jacobsen","year":"2007","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib70","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01859-21","article-title":"Biomarkers that correlate with active pulmonary tuberculosis treatment response: a systematic review and meta-analysis","volume":"60","author":"Zimmer","year":"2022","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.micpath.2025.107794_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.419","article-title":"Mycobacterium tuberculosis: immune response, biomarkers, and therapeutic intervention","volume":"5","author":"Zhuang","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.micpath.2025.107794_bib72","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/S1473-3099(18)30111-7","article-title":"Tuberculosis: advances and challenges in development of new diagnostics and biomarkers","volume":"18","author":"Walzl","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib73","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib74","article-title":"Investigating the efficacy and mechanisms of action of tuberculosis drugs","volume":"15","author":"Zade","year":"2024","journal-title":"Sys. Rev. Pharm."},{"key":"10.1016\/j.micpath.2025.107794_bib75","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.biopha.2017.04.105","article-title":"New drugs for the treatment of Mycobacterium tuberculosis infection","volume":"91","author":"AlMatar","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.micpath.2025.107794_bib76","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/cid\/ciac176","article-title":"Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid, and other second-line drugs","volume":"75","author":"Huerga","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijtb.2023.05.005","article-title":"Efficacy and safety of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in adults: a systematic review and meta-analysis","volume":"71","author":"Ahmed","year":"2024","journal-title":"Indian J. Tubercul."},{"key":"10.1016\/j.micpath.2025.107794_bib78","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.5588\/ijtld.15.0389","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015, the international journal of tuberculosis and lung disease","volume":"19","author":"Zhang","year":"2015","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib79","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41579-019-0273-7","article-title":"The mycobacterial cell envelope - a moving target","volume":"18","author":"Dulberger","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.micpath.2025.107794_bib80","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/fmb.11.123","article-title":"Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets","volume":"7","author":"Jankute","year":"2012","journal-title":"Future Microbiol."},{"key":"10.1016\/j.micpath.2025.107794_bib81","doi-asserted-by":"crossref","first-page":"13881","DOI":"10.1073\/pnas.2235848100","article-title":"The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance","volume":"100","author":"Rawat","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.micpath.2025.107794_bib82","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/358591a0","article-title":"The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis","volume":"358","author":"Zhang","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.micpath.2025.107794_bib83","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1128\/AAC.47.4.1241-1250.2003","article-title":"Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis","volume":"47","author":"Ramaswamy","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib84","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1126\/science.279.5347.98","article-title":"Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis","volume":"279","author":"Rozwarski","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.micpath.2025.107794_bib85","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/jac\/dkt090","article-title":"High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations","volume":"68","author":"Machado","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib86","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1080\/22221751.2020.1785334","article-title":"Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis","volume":"9","author":"Swain","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.micpath.2025.107794_bib87","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1128\/AAC.01775-13","article-title":"Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib88","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jiph.2018.04.005","article-title":"Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis","volume":"11","author":"Zaw","year":"2018","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.micpath.2025.107794_bib89","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1038\/ncomms5306","article-title":"Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis","volume":"5","author":"Nandakumar","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2025.107794_bib90","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1038\/s41467-018-06667-3","article-title":"Rifampicin can induce antibiotic tolerance in mycobacteria via paradoxical changes in rpoB transcription","volume":"9","author":"Zhu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2025.107794_bib91","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1164\/rccm.201011-1924OC","article-title":"Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux","volume":"184","author":"Louw","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.micpath.2025.107794_bib92","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1128\/AAC.48.4.1281-1288.2004","article-title":"Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity","volume":"48","author":"Aubry","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib93","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/AAC.48.2.596-601.2004","article-title":"Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates","volume":"48","author":"Cheng","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib94","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1128\/AAC.50.1.104-112.2006","article-title":"Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes","volume":"50","author":"Aubry","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib95","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1128\/AAC.06227-11","article-title":"rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains","volume":"56","author":"Beckert","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib96","doi-asserted-by":"crossref","first-page":"10062","DOI":"10.1093\/nar\/gkt751","article-title":"The mycobacterial antibiotic resistance determinant WhiB7 acts as a transcriptional activator by binding the primary sigma factor SigA (RpoV)","volume":"41","author":"Burian","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.micpath.2025.107794_bib97","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.micpath.2025.107794_bib98","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00141-20","article-title":"Mechanisms of drug-induced tolerance in Mycobacterium tuberculosis","volume":"34","author":"Goossens","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.micpath.2025.107794_bib99","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001065","article-title":"Metabolic regulation of mycobacterial growth and antibiotic sensitivity","volume":"9","author":"Baek","year":"2011","journal-title":"PLoS Biol."},{"key":"10.1016\/j.micpath.2025.107794_bib101","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4155\/fmc.10.219","article-title":"Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling","volume":"2","author":"Tud\u00f3","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.micpath.2025.107794_bib102","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1128\/AAC.49.4.1483-1494.2005","article-title":"Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations","volume":"49","author":"Wiuff","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib103","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.tube.2003.12.014","article-title":"Regulation of the Mycobacterium tuberculosis PE\/PPE genes","volume":"84","author":"Voskuil","year":"2004","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2025.107794_bib104","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.tube.2011.04.004","article-title":"The PE and PPE proteins of Mycobacterium tuberculosis","volume":"91","author":"Mukhopadhyay","year":"2011","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2025.107794_bib105","series-title":"Advancing the Understanding of the PE\/PPE Protein Families through PPE_MPTR Protein Expression and Analysis of Pe\/ppe Single Nucleotide Variants in Differentially Drug Sensitive Mycobacterium tuberculosis","author":"Bartizal","year":"2022"},{"key":"10.1016\/j.micpath.2025.107794_bib106","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1089\/dna.2019.4852","article-title":"Molecular basis underlying host immunity subversion by Mycobacterium tuberculosis PE\/PPE family molecules","volume":"38","author":"Yu","year":"2019","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.micpath.2025.107794_bib107","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12866-024-03352-y","article-title":"PE\/PPE mutations in the transmission of Mycobacterium tuberculosis in China revealed by whole genome sequencing","volume":"24","author":"Fang","year":"2024","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.micpath.2025.107794_bib108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit c of mycobacterial ATP synthase","volume":"3","author":"Koul","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.micpath.2025.107794_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.micpath.2025.107794_bib110","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.micpath.2025.107794_bib111","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib112","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jiph.2022.08.016","article-title":"An insight into the discovery, clinical studies, compositions, and patents of macozinone: a drug targeting the DprE1 enzyme of Mycobacterium tuberculosis","volume":"15","author":"Imran","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.micpath.2025.107794_bib113","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01123-22","article-title":"Safety, tolerability, pharmacokinetics, and metabolism of Telacebec (Q203) for the treatment of tuberculosis: a randomized, placebo-controlled, multiple ascending dose phase 1B trial","volume":"67","author":"Kim","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib114","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib115","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1128\/AAC.01179-10","article-title":"Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis","volume":"55","author":"Wallis","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib116","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.drudis.2016.11.015","article-title":"Recent developments in natural product-based drug discovery for tuberculosis","volume":"22","author":"Dong","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.micpath.2025.107794_bib117","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1126\/science.aaa4690","article-title":"Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins","volume":"348","author":"Kling","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.micpath.2025.107794_bib118","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1002\/anie.201101740","article-title":"The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease","volume":"50","author":"Schmitt","year":"2011","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.micpath.2025.107794_bib119","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1039\/C6OB00801A","article-title":"Total synthesis of desoxycyclomarin C and the cyclomarazines A and B","volume":"14","author":"Barbie","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.micpath.2025.107794_bib120","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1128\/AAC.04054-14","article-title":"The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo","volume":"59","author":"Gao","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107794_bib121","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.chembiol.2014.01.014","article-title":"Lassomycin, a ribosomally synthesized cyclic peptide, kills Mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2","volume":"21","author":"Gavrish","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.micpath.2025.107794_bib122","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1021\/np3007167","article-title":"Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents","volume":"76","author":"Hwang","year":"2013","journal-title":"J. Nat. Prod."},{"issue":"Suppl 2","key":"10.1016\/j.micpath.2025.107794_bib123","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1093\/cid\/cis337","article-title":"Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection","volume":"55","author":"Sears","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107794_bib124","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1021\/acs.orglett.5b01602","article-title":"Total synthesis of the glycosylated macrolide antibiotic fidaxomicin","volume":"17","author":"Kaufmann","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.micpath.2025.107794_bib125","article-title":"Influence of aromatic essential oil nursing on mental state of patients undergoing laparoscopic cholecystectomy: a protocol for systematic review and meta-analysis","volume":"101","author":"Liu","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.micpath.2025.107794_bib126","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nm.3458","article-title":"Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux","volume":"20","author":"Lee","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.micpath.2025.107794_bib127","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1021\/acsinfecdis.6b00158","article-title":"Structure-activity relationships of Spectinamide antituberculosis agents: a dissection of ribosomal inhibition and native efflux avoidance contributions","volume":"3","author":"Liu","year":"2017","journal-title":"ACS Infect. Dis."},{"issue":"4","key":"10.1016\/j.micpath.2025.107794_bib128","doi-asserted-by":"crossref","DOI":"10.1358\/dof.2018.043.04.2795153","article-title":"Delpazolid. Oxazolidinone antibiotic, Treatment of tuberculosis","volume":"43","author":"Kaul","year":"2018","journal-title":"Drugs Future"},{"key":"10.1016\/j.micpath.2025.107794_bib129","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1038\/s41598-017-06289-7","article-title":"Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.107794_bib130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.tube.2013.09.002","article-title":"Cyclic di-GMP mediates Mycobacterium tuberculosis dormancy and pathogenecity","volume":"93","author":"Hong","year":"2013","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.micpath.2025.107794_bib131","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025005194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025005194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T18:50:30Z","timestamp":1752000630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401025005194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":131,"alternative-id":["S0882401025005194"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2025.107794","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of antimicrobial drugs in Mycobacterium tuberculosis and research progress","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2025.107794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107794"}}